$4.47
5.05% day before yesterday
Nasdaq, May 30, 10:03 pm CET
ISIN
US0021201035
Symbol
ATYR
Sector
Industry

aTyr Pharma, Inc. Stock price

$4.47
+1.00 28.82% 1M
+0.91 25.56% 6M
+0.85 23.48% YTD
+2.71 153.98% 1Y
+1.63 57.39% 3Y
+0.59 15.21% 5Y
-324.25 98.64% 10Y
Nasdaq, Closing price Fri, May 30 2025
+0.22 5.05%
ISIN
US0021201035
Symbol
ATYR
Sector
Industry

Key metrics

Market capitalization $397.85m
Enterprise Value $322.80m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.30
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-67.05m
Free Cash Flow (TTM) Free Cash Flow $-62.21m
Cash position $76.35m
EPS (TTM) EPS $-0.73
P/E forward negative
P/S forward 196.61
EV/Sales forward 159.52
Short interest 17.39%
Show more

Is aTyr Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

aTyr Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a aTyr Pharma, Inc. forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a aTyr Pharma, Inc. forecast:

Buy
100%

Financial data from aTyr Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
9% 9%
-
- Research and Development Expense 53 53
14% 14%
-
-66 -66
14% 14%
-
- Depreciation and Amortization 0.70 0.70
1% 1%
-
EBIT (Operating Income) EBIT -67 -67
14% 14%
-
Net Profit -63 -63
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about aTyr Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

aTyr Pharma, Inc. Stock News

Neutral
GlobeNewsWire
12 days ago
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.
Neutral
GlobeNewsWire
13 days ago
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod in pulmonary sarcoidosis is higher than previously estimated with increased morbidity.
Neutral
GlobeNewsWire
16 days ago
SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purch...
More aTyr Pharma, Inc. News

Company Profile

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Sanjay Shukla
Founded 2005
Website www.atyrpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today